Clinical trials
Radiation Injuries trials in China with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
15 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2016 | 1 |
| 2017 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 7 |
| Recruiting | 4 |
| Completed | 2 |
| Active, not recruiting | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 4 |
| Fujian Cancer Hospital | 1 |
| Hebei Provincial Hospital of Traditional Chinese Medicine | 1 |
| Jiangxi Provincial Cancer Hospital | 1 |
| Peking Union Medical College Hospital | 1 |
| Peking University Third Hospital | 1 |
| Shu lian Wang | 1 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| Sun Yat-sen University | 1 |
| The University of Hong Kong-Shenzhen Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Radiation Injuries | 15 |
| Breast Neoplasms | 3 |
| Uterine Cervical Neoplasms | 3 |
| Head and Neck Neoplasms | 2 |
| Sarcoma | 2 |
| Glioma | 1 |
| Heart Injuries | 1 |
| Lung Neoplasms | 1 |
| Neuralgia | 1 |
| Prostatic Neoplasms | 1 |
Trials
Showing 1 to 15 of 15. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.